2021 Scientific Sessions

TAVR in the 65-75 Year Old: How Do You Choose?

Kimberly A. Skelding, M.D., FSCAI, Robert Wood Johnson Barnabas Health, Ridgewood, NJ
Kimberly A. Skelding, M.D., FSCAI, Robert Wood Johnson Barnabas Health, Ridgewood, NJ

Learning Objectives:
  1. Question data on valve durability, showing major trials and flaws.
  2. Give two patient examples in which TAVR first is controversial, but best fit for a young patient (and outcome shown if possible).
  3. Describe concepts of shared decision making, presence in guidelines.
Keywords: Structural Heart Disease (SHD) and TAVI/TAVR/Aortic Valve